Eli Lilly and Company (LLY) Stock Analysis
Oversold Bounce setup · Temp Headwind edge
Healthcare · Drug Manufacturers - General
Wait for pullback to $905.54. Weak momentum — blocks BUY_NOW at $907.27. Engine's entry $905.54 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Mounjaro and Zepbound (56.0%); Leverage penalty (D/E 1.7): -1.0.
Eli Lilly discovers and markets human pharmaceutical products in a single segment globally. Key products include Mounjaro/Zepbound (GLP-1 class, 56% of 2025 revenues), Verzenio, Trulicity, Taltz, and Jardiance, which collectively accounted for 82% of 2025 revenues.
Wait for pullback to $905.54. Weak momentum — blocks BUY_NOW at $907.27. Engine's entry $905.54 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Mounjaro and Zepbound (56.0%); Leverage penalty (D/E 1.7): -1.0. Chart setup: Oversold RSI 24, near Bollinger lower, volume surge. Earnings in 0 days. Wait until post-earnings. Score 6.5/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 0d<=7d. Suitability: conservative.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMounjaro and Zepbound56%10-K Item 1A: 'Mounjaro and Zepbound accounted for 56 percent of our total revenues in 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $905.54. Weak momentum — blocks BUY_NOW at $907.27. Engine's entry $905.54 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Mounjaro and Zepbound (56.0%); Leverage penalty (D/E 1.7): -1.0. Chart setup: Oversold RSI 24, near Bollinger lower, volume surge. Earnings in 0 days. Wait until post-earnings. Target $1082.11 (+19.3%), stop $853.62 (−6.3%), Setup A.R:R 4.9:1. Score 6.5/10, moderate confidence.
Take-profit target: $1082.11 (+31.1% upside). Target $1082.11 (+19.3%), stop $853.62 (−6.3%), Setup A.R:R 4.9:1. Stop-loss: $853.62.
Concentration risk — Product: Mounjaro and Zepbound (56.0%); Leverage penalty (D/E 1.7): -1.0.
Eli Lilly and Company trades at a P/E of 37.0 (forward 20.2). TrendMatrix value score: 5.0/10. Verdict: Buy (Wait for Entry).
39 analysts cover LLY with a consensus score of 4.1/5. Average price target: $1202.
What does Eli Lilly and Company do?Eli Lilly discovers and markets human pharmaceutical products in a single segment globally. Key products include...
Eli Lilly discovers and markets human pharmaceutical products in a single segment globally. Key products include Mounjaro/Zepbound (GLP-1 class, 56% of 2025 revenues), Verzenio, Trulicity, Taltz, and Jardiance, which collectively accounted for 82% of 2025 revenues.